EBNA1 Antigen Assay for Early NPC IgA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NPC screening methods lack sufficient specificity and sensitivity for early detection, particularly in low-incidence populations, necessitating improved biomarkers for accurate risk assessment and screening.
Innovation Solution
A device comprising a protein-binding substrate with an isolated EBV EBNA1 protein, produced in a mammalian cell, that has at least 50% of the GA region deleted, specifically binding to serum IgA of NPC patients, enhancing the detection of NPC risk through improved biomarker specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional NPC screening methods are used, then screening coverage is achieved, but sensitivity and specificity for early detection are insufficient
Solution Approach 1:
The patent modifies the EBNA1 protein by deleting at least 50% of the GA region, fundamentally changing the protein's structure and properties. This parameter change in the biomarker creates a novel assay that achieves superior sensitivity and specificity for early NPC detection compared to conventional screening methods using full-length or unmodified EBNA1 protein.
2Measurement precision
If full-length EBNA1 protein is used for detection, then comprehensive antigen coverage is achieved, but specificity for early NPC detection is reduced
Solution Approach 1:
The patent extracts and removes the GA-rich region (at least 50% deletion) from the full-length EBNA1 protein. This extraction of the problematic GA region eliminates sources of non-specific binding and background interference, thereby enhancing the specificity of the biomarker for early NPC detection while maintaining the essential immunogenic regions.
3Reliability
If early detection methods are implemented, then survival rates can be improved, but current methods lack sufficient sensitivity in low-incidence populations
Solution Approach 1:
The modified EBNA1 protein with deleted GA region exhibits enhanced binding affinity and reduced background noise, enabling detection of lower concentrations of anti-EBNA1 IgA antibodies. This parameter change in the antigen structure allows the assay to reliably detect early NPC even in low-incidence populations where antibody concentrations are minimal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device provides enhanced sensitivity and specificity in NPC screening, enabling early detection and monitoring, potentially reducing the incidence of late-stage diagnoses and improving treatment outcomes.
Implementation Method 1
an isolated EBV EBNA1 protein produced in a mammalian cell that binds serum IgA of an NPC patient
Data Source
AI summary
Early Nasopharyngeal Carcinoma (NPC) detection methods, devices, and kits are provided utilizing novel Epstein-Barr Virus (EBV) EBNA1 antigens to detect serum anti-EBNA1 IgA antibodies with superior correlation to NPC development within four years.